Development of Asymmetric Facial Depigmentation in a Patient Treated with Dasatinib with New-Onset Hypovitaminosis D: Case Report and Review of the Literature
Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) used to treat imatinib-resistant chronic myelogenous leukemia (CML), as well as other Philadelphia chromosome-positive lymphoproliferative disorders. While the most commonly reported cutaneous side effects with this therapy include a m...
Збережено в:
| Автори: | , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
Wiley
2017-01-01
|
| Серія: | Case Reports in Dermatological Medicine |
| Онлайн доступ: | http://dx.doi.org/10.1155/2017/9359086 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|